Detail akcie Bioporto online

Business Summary: Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, BioPorto A/S revenues increased 20% to DKR24.4M. Net loss decreased 11% to DKR45.3M. Revenues reflect The NGAL test segment increase of 57% to DKR15.2M, North America segment increase of 18% to DKR13.5M, Europe segment increase of 18% to DKR7.5M. Basic Earnings per Share excluding Extraordinary Items increased from -DKR0.15 to -DKR0.12.